Show simple item record

Editorial: Innovative biologics and drugs to target renal inflammation

dc.contributor.authorGriffin, Matthew D.
dc.contributor.authorSwaminathan, Sundararaman
dc.date.accessioned2021-01-04T14:31:08Z
dc.date.available2021-01-04T14:31:08Z
dc.date.issued2020-02-06
dc.identifier.citationGriffin, Matthew D., & Swaminathan, Sundararaman. (2020). Editorial: Innovative Biologics and Drugs to Target Renal Inflammation. Frontiers in Pharmacology, 11(38). doi:10.3389/fphar.2020.00038en_IE
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/10379/16398
dc.description.abstract[No abstract available]en_IE
dc.description.sponsorshipSS is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number 1RO1DK103043. MG is supported by grants from the European Commission [Horizon 2020 Collaborative Health Project NEPHSTROM (grant number 634086) and FP7 Collaborative Health Project VISICORT (grant number 602470)] and from Science Foundation Ireland [CÚRAM Research Centre (grant number 13/RC/2073)] and by the European Regional Development Fund.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherFrontiers Mediaen_IE
dc.relation.ispartofFrontiers in Pharmacologyen
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjectChronic Kidney Diseaseen_IE
dc.subjectAcute Kidney Injuryen_IE
dc.subjectInflammationen_IE
dc.subjectTherapeutic Targetsen_IE
dc.subjectDiabetic Nephropathyen_IE
dc.subjectSepsisen_IE
dc.subjectInterstitial Fibrosisen_IE
dc.subjectBiologic Agentsen_IE
dc.subjectCHRONIC KIDNEY-DISEASEen_IE
dc.subjectINHIBITIONen_IE
dc.subjectBURDENen_IE
dc.titleEditorial: Innovative biologics and drugs to target renal inflammationen_IE
dc.typeArticleen_IE
dc.date.updated2020-12-19T17:28:37Z
dc.identifier.doi10.3389/fphar.2020.00038
dc.local.publishedsourcehttps://doi.org/10.3389/fphar.2020.00038en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderNational Institutes of Healthen_IE
dc.contributor.funderHorizon 2020en_IE
dc.contributor.funderSeventh Framework Programmeen_IE
dc.contributor.funderScience Foundation Irelanden_IE
dc.contributor.funderEuropean Regional Development Funden_IE
dc.internal.rssid20134571
dc.local.contactMatthew Dallas Griffin, Remedi, Biomedical Sciences Buil, Corrib Village, Dangan, Nui Galway. 5436 Email: matthew.griffin@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
dcterms.projectinfo:eu-repo/grantAgreement/EC/H2020::RIA/634086/EU/Novel Stromal Cell Therapy for Diabetic Kidney Disease/NEPHSTROMen_IE
dcterms.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/602470/EU/Adverse Immune Signatures and their Prevention in Corneal Transplantation/VISICORTen_IE
dcterms.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/602470/EU/Adverse Immune Signatures and their Prevention in Corneal Transplantation/VISICORTen_IE
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/C�RAM - Centre for Research in Medical Devices/en_IE
nui.item.downloads102


Files in this item

Thumbnail
Name:
license.txt
Size:
5.659Kb
Format:
Text file
View/Open
Thumbnail
Name:
Griffin_and_Swaminathan_Editor ...
Size:
204.1Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland